Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Glossary

The Paul-Ehrlich-Institut has developed the definitions in this glossary to help users understand regulatory and biomedical terminology. Definitions may differ from those given in German and European Union legislation and medicine. Many definitions correspond to the glossary entries on the pages of the European Medicines Agency (EMA).

Market Exclusivity

The 10-year period after the marketing authorisation of an orphan medicine when similar medicines for the same indication cannot be placed on the market.

Updated: 21.11.2019

Marketing Authorisation Holder

The company or other legal entity that has the authorisation to market a medicine in one, several or all European Union Member States.

Updated: 21.11.2019

Mock-up Vaccine

A vaccine that contains a strain of flu virus which could cause a pandemic. The mock-up procedure allows an accelerated development of a vaccine in advance of a pandemic.

Updated: 21.11.2019

Mutual Recognition

A procedure through which an authorisation of a medicine in one European Union Member State is recognised by another Member State.

Updated: 21.11.2019